- Participation in France BioLead reflects the Company's
growing focus on innovation for bioproduction in line with its
strategy to accelerate advancements in genomics
- DNA combing technology is a unique tool for characterization
of transformed cells used for quality control throughout the
bioproduction cycle
Regulatory News:
Genomic Vision (Paris:GV) (FR0011799907 – GV, – the
“Company”), a Euronext-listed biotechnology company that
develops products and services dedicated to the analyses and
control of changes in the genome, is pleased to announce that it
has joined France BioLead.
The France BioLead Association was officially launched in
December 2022 by the French government and 15 founding members,
players from all the biomanufacturing value chains. Its mission is
to structure, steer, support, animate and promote the French
biomanufacturing industry and its players. Its purpose is to
support the development of the various technological value chains
of a sovereign and innovative French biomanufacturing industry
throughout the life cycle of the biomedical product, to ensure the
availability of biomedical products for patients, and to build an
attractive and recognized industry, particularly
internationally.
Its three major objectives for 2030 are: to double the
proportion of biomedical products produced in France, to double the
number of jobs in the sector (from 10,000 to 20,000), and to enable
the emergence of at least one new unicorn and five new biotech
SMEs.
Aaron Bensimon, Chief Executive Officer of Genomic Vision
commented: “As we increase our focus on bioproduction, a part
of our new strategic orientation, Genomic Vision is proud to be
part of the first cohort of members of the France BioLead
association, aiming to accelerate the development of the French
bioproduction sector. Our DNA combing technology is a valuable tool
for characterization of transformed cells used for quality control
throughout the bioproduction cycle. We will work within France
BioLead to establish the French bioproduction sector as a global
leader along with our fellow members, including many international
players. Lionel Seltz, our CFO, will coordinate the working group
for financing topics.”
As part of its membership, Genomic Vision will have access to
France BioLead’s network of experts and industry leaders, as well
as opportunities to participate in a range of events and
initiatives, including industry conferences and seminars.
ABOUT GENOMIC VISION
GENOMIC VISION is a biotechnology company developing products
and services dedicated to the structural and functional analysis of
genome modifications as well as to the quality and safety control
of these modifications, in particular in genome editing
technologies and biomanufacturing processes. Genomic Vision
proprietary products and services, based on DNA combing technology
and artificial intelligence, provide robust quantitative
measurements needed for high confidence characterization of DNA
alteration in the genome. These products and services are also used
for monitoring DNA replication in cells to improve anti-cancerous
drugs development. Genomic Vision, based near Paris in Bagneux, is
a public company listed in compartment C of Euronext’s regulated
market in Paris (Euronext: GV – ISIN: FR0011799907).
www.genomicvision.com
ABOUT FRANCE BIOLEAD
France BioLead, the association for the production of
biomedicines in France, brings together all the players in the
French biomanufacturing sector, including manufacturers
(pharmaceutical and biotechnology companies, CDMOs, CROs, equipment
manufacturers, suppliers of technological solutions and
consumables), academic research, training providers, the French
government and competitive clusters, associations and professional
unions. Its ambition is to structure and manage a unique French
biomanufacturing industry with the support of the French
government, to make France a leader in biomanufacturing in Europe
and restore France's independence and sovereignty in this field.
France BioLead was officially launched in December 2022, in the
presence of the Minister of Roland Lescure, Minister Delegate in
charge of Industry, with the support of François Braun, Minister of
Health and Prevention and Sylvie Retailleau, Minister of Higher
Education and Research, as well as its 15 founding members, players
from all biomanufacturing value chains: ALLIS-NA, Capgemini, CEA,
Clean Biologics, Enosis Santé, France Biotech, Genopole, GTP
Bioways, Inserm, Leem, Merck, Polepharma, Sanofi, Servier, Thermo
Fisher Scientific.
Member of the CAC® Mid & Small and CAC® All-Tradable
indices
FORWARD LOOKING STATEMENT
Genomic Vision has set up a financing line in the form of
convertible notes with warrants (OCABSA) with Winance, which does
not intend to remain a shareholder of the company, after receiving
the shares resulting from the conversion or exercise of the
securities.
The shares resulting from the conversion or exercise of the
aforementioned securities will, in general, be sold on the market
very quickly, which is likely to create strong downward pressure on
the share price as well as a strong dilution.
Shareholders could therefore suffer a loss of their invested
capital due to a significant decrease in the value of the company's
shares. The company has carried out several dilutive financing
operations, and investors are advised to be very careful before
making a decision to invest in the company's securities.
This press release contains implicitly or explicitly certain
forward-looking statements concerning Genomic Vision and its
business. Such forward-looking statements are based on assumptions
that Genomic Vision considers to be reasonable. However, there can
be no assurance that such forward-looking statements will be
verified, which statements are subject to numerous risks, including
the risks set forth in the “Risk Factors” section of the universal
registration document filed with the AMF on April 14, 2022 under
reference number R.22-0293, as updated by the amendment filed with
the AMF on May 20, 2022, under number D.22-0293-A01, available on
the web site of Genomic Vision (www.genomicvision.com) and to the
development of economic conditions, financial markets and the
markets in which Genomic Vision operates. The forward-looking
statements contained in this press release are also subject to
risks not yet known to Genomic Vision or not currently considered
material by Genomic Vision. The occurrence of all or part of such
risks could cause actual results, financial conditions, performance
or achievements of Genomic Vision to be materially different from
such forward-looking statements.
This press release and the information contained herein do not
constitute and should not be construed as an offer or an invitation
to sell or subscribe, or the solicitation of any order or
invitation to purchase or subscribe for Genomic Vision shares in
any country. The distribution of this press release in certain
countries may be a breach of applicable laws. The persons in
possession of this press release must inquire about any local
restrictions and comply with these restrictions.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20230402005048/en/
Genomic Vision Aaron Bensimon Chairman of the Management
Board Tel.: +33 1 49 08 07 51 investisseurs@genomicvision.com
Ulysse Communication Media Relations Bruno Arabian Tél.:
+33 1 42 68 29 70 barabian@ulysse-communication.com
Consilium Strategic Communications International Investor
Relations & Strategic Communications Tel.: +44 (0) 20 3709 5700
GenomicVision@consilium-comms.com
NewCap France Investor Relations & Strategic
Communications Tel.: +33 1 44 71 94 94 gv@newcap.eu
Guerrero Ventures (TSXV:GV)
Historical Stock Chart
From May 2024 to Jun 2024
Guerrero Ventures (TSXV:GV)
Historical Stock Chart
From Jun 2023 to Jun 2024